We seek him here...

The fibrocyte in pulmonary hypertension: we seek him here, we seek him there.

T he fibrocyte is one of many populations of bone marrowderived cells that can be detected in the peripheral blood and is considered to represent a mesenchymal progenitor cell [1]. The fibrocyte, as we currently understand this term, was originally described by BUCALA et al. [2] in 1994 and is defined by the expression of a variety of cell surface antigens, including the stem cell marker CD34, ...

How did we get here?

I t is rare that science owes a debt to law. To lawmakers, surely, such as those who regularly make generous appropriations to the National Science Foundation and the National Institutes of Health. But law, in the sense of the process and products of litigation? It’s hard to imagine. But this special supplement is deeply in debt to law in just that sense. The funding that supports the research ...

How Did We Get Here?

W hen we talk among ourselves about our business, we use lots of abbreviations and acronyms. We take a lot of things for granted. To understand what I’m talking about all you need to do is try to explain how you get paid to somebody. AWP, WAC, discount, PBM, RA, EOB, DIR, copay, insured amount, rebate, clawback, etc. This is the barrier we face when talking to legislators. We are in a complicat...

How did we get here and where are we going?

We think we see a pattern emerging here.

For more than 30 years, the quest for interventions that can preserve viability in ischemic myocardium has been ongoing. The search began with the pioneering studies of Maroko and colleagues in the 1970s.1 Although reperfusion therapy has emerged as a great success story, we are still on a quest for an intervention that can preserve viability until blood flow can be restored in the setting of a...